Navigation Links
CEL-SCI Takes Delivery of New Manufacturing Facility
Date:10/9/2008

VIENNA, Va., Oct. 9 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE: CVM) announced today that it has taken delivery of the new manufacturing facility for its lead drug Multikine(R). This dedicated facility, located in the Baltimore area, will produce the Multikine that will be used for CEL-SCI's pivotal Phase III clinical trial for first-line therapy of previously untreated head and neck cancer patients, and subsequently for sale following approval of the drug. The facility, which cost about $22 million to build, is state of the art and will soon be commercial ready. As it stands today, the facility can produce about $600 million worth of drug per year. Within one year it can be built out to product almost $2 billion worth of drug per year.

Geert Kersten, CEL-SCI's Chief Executive Officer said, "Multikine started with the idea that activating the immune system to fight cancer could be beneficial and successful, as long as you could activate the immune system before it was weakened by surgery, radiation and chemotherapy. Our clinical studies showed significant benefit to the cancer patients treated with Multikine. We are now in the home stretch. Having our own Multikine dedicated manufacturing facility gives us control and eliminates a great deal of risk from our product development. Our next step is to completely validate the facility and to bring it on line for manufacturing."

CEL-SCI is developing Multikine for approval as a first line indication in head and neck cancer. To that end, the Company's upcoming Phase III clinical trial is an 800 patient clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any conventional cancer treatmen
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Ground-Breaking Conference Takes on Abortion
9. White Paper Advises Pharma Manufacturers on How to Select an Aseptic Fill/Finish Contractor, Avoid the Most Common Mistakes
10. Ganeden Biotech Takes Sustenex(TM) National with GanedenBC30 Probiotic
11. Tepper School Team Takes Top Honors at Global Moot Corp(R) Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --  ISN has released its third annual U.S. ... publication series. With data aggregated from over eight billion ... its online contractor management platform, ISNetworld, this three-part series ... statistics. The Contractor Performance ... available in two industry specific volumes: Oil & ...
(Date:12/17/2014)... 17, 2014 Achim Noack has been ... Stoller Group. In this position, Noack will assist Jerry ... matters, develop marketing strategy and supervise global marketing management ... “Achim has tremendous knowledge and experience in the crop ... “His experience and innovative thinking will be a great ...
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... BETHESDA, Md., Sept. 16 Micromet, Inc. (Nasdaq: MITI ), ... inflammation and autoimmune diseases, today announced that its President and CEO, Dr. ... September 22, 2009 in New York City. A simultaneous webcast of ... , , ...
... ... RPCI is to develop, optimize, and perform high-throughput insertional mutagenesis screens to identify potential ... ... research company which performs high-throughput (HT) RNAi and peptide genetic screens for novel therapeutic ...
... , , CINCINNATI, Sept. 16 ... research organization, today announced the Company will participate in the upcoming ... Grand Hyatt New York Hotel in New York City. , ... , , Kendle,s formal presentation will be given ...
Cached Biology Technology:Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 2Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009 3CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 2CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc. 3Kendle to Present at UBS Global Life Sciences Conference 2
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... A new study that provides a snapshot of a ... of physical activity are strongly associated with being overweight or ... in fruits and vegetables did little to offset the effect ... who were mostly sedentary. Instead, exercise seemed to be the ...
... March 24 An experimental vaccine against an abnormal protein ... onset of inflammatory bowel disease (IBD) and in turn prevent ... of Pittsburgh School of Medicine. Their findings are reported this ... the American Association for Cancer Research. People with chronic ...
... A Worcester Polytechnic Institute (WPI) research team has ... Institutes of Health (NIH) to continue a groundbreaking study ... that will enable physicians to predict the likelihood of ... and strokes. Led by Dalin Tang, PhD, professor of ...
Cached Biology News:Rochester study connects workplace turmoil, stress and obesity 2Rochester study connects workplace turmoil, stress and obesity 3Rochester study connects workplace turmoil, stress and obesity 4Vaccine could delay bowel inflammation and colon cancer, says Pitt research 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
...
...
... PCR Cloning Kit offers the fastest ... cloning of blunt-end PCR products amplified ... includes the linearized and topoisomerase I-activated ... ligations without ligase (1). The pCR-Blunt ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: